A Gene Panel Associated With Abemaciclib Utility in ESR1 -Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression.
Jamie O BrettTaronish D DubashGabriela N JohnsonAndrzej NiemierkoVeronica MariottiLeslie S L KimJing XiApurva PandeySiobhan DunneAzadeh NasrazadaniMaxwell R LloydAvinash KambadakoneLaura M SpringDouglas S MicalizziMaristela L OnozatoDante CheUtthara NayarAdam M BrufskyKevin M KalinskyCynthia X MaJoyce O'ShaughnessyHyo S HanAnthony J IafrateLianne Y RyanDejan JuricBeverly MoyLeif W EllisenShyamala MaheswaranNikhil WagleDaniel A HaberAditya BardiaSeth A WanderPublished in: JCO precision oncology (2023)
For ESR1-MUT MBC with resistance to ET and palbociclib, PFS on abemaciclib is longer for patients with CDKi-R(-) than CDKi-R(+). Although a small and retrospective data set, this is the first demonstration of a genomic panel associated with abemaciclib sensitivity in the postpalbociclib setting. Future directions include testing and improving this panel in additional data sets, to guide therapy selection for patients with HR+/HER2- MBC.